EGT+Fisetin+Urolithin A
Natural health product licensed in Canada
If this product were sold in France
- Conditions légales
Trigonella foenum-graecum L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux femmes enceintes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| 2-(3,4-Dihydroxyphényl)-3,7-dihydroxy-4H-1-benzopyran-4-one | 20 mg | Not calculated |
| 1,4-diaminobutane, N-(3-aminopropyl)- Source : Spermidine trichlorhydrate | 0.6 mg | Not calculated |
| Acide 1H-pyrrolo(2,3-f)quinoline-2,7,9-tricarboxylique, 4,5-dihydro-4,5-dioxo- Source : Pyrroloquinoline quinone disodium salt | 20 mg | Not calculated |
| Sel interne de (alphaS)-alpha-Carboxy-2,3-dihydro-N,N,N-triméthyl-2-thioxo-1H-imidazole-4-ethanaminium Source : Ergothionéine | 25 mg | Not calculated |
| Acide 2',4,4'-trihydroxy-biphénylcarboxylique, delta-lactone | 200 mg | Not calculated |
| Ubiquinol Source : Ubiquinol | 30 mg | Not calculated |
| Malus domestica Source : Malus domestica - Fruit Extract : Matériel brut sec Extraction ratio : 8:1 Dry plant equivalent : 80 mg | 10 mg | Not calculated |
| Collagène hydrolysé Potency : 2.6 mg L-Lysine | 37.5 mg | Not calculated |
| Trigonella foenum-graecum Source : Trigonella foenum-graecum - Graine Extract : Matériel brut sec Extraction ratio : 20:1 Dry plant equivalent : 600 mg | 30 mg | Not calculated |
| Superoxyde dismutase | 5 mg | Not calculated |
| Superoxyde dismutase | 1,000 UI | Not calculated |
Non-medicinal ingredients
Cellulose microcristalline, Stéarate de magnésium, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18 years | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Source of/Provides (an) antioxidant(s) that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Helps to maintain and/or support cardiovascular health. Source of (an) antioxidant(s)/Provides (an) antioxidant(s).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Product record
- Other names
- EGT Complex Super Antioxdant, Fisetin Complex Super Antioxdant, Urolithin A Complex Super Antioxdant
- Licence holder
- Ergo & Lux Nutrition Innovation Lab Inc.
- NPN or DIN-HM
- 80147908
- Status
- Active licence
- Licence date
- 18 March 2026
- Revision date
- Not provided
- Form
- Capsule, dur
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
Source
Official Health Canada record, licence 80147908
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ubiquinol
Read the warning, when it applies and the studies cited
UBIQUINOL
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Langsjoen and Langsjoen 2008; Rosenfeldt et al. 2007; Engelsen et al. 2003; Singh et al. 1999; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (6)
- Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. PubMed Clinical trial
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Applies to products providing more than 100 mg of Ubiquinol, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Langsjoen and Langsjoen 2008; Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (4)
- Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. PubMed Clinical trial
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
- Collagène hydrolysé
Read the warning, when it applies and the studies cited
Hydrolyzed Collagen
Route of administration: Oral
Cautions and warnings
Condition of application: Joint pain.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
Applies to products providing more than 2.8 g hydrolyzed collagen, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Shils et al. 2006; Goldman and Ausiello 2004).
Sources cited by Health Canada (2)
- Goldman L, Ausiello D, editors. Cecil Textbook of Medicine, Volume 1, 22nd edition. Philadelphia (PA): Saunders; 2004.
- Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, editors. Modern Nutrition in Health and Disease, 10th edition. Philadelphia (PA): Lippincott Williams and Wilkins, 2006.
Known adverse reactions
When using this product you may experience gastrointestinal discomfort/disturbances (Moskowitz 2000).
Sources cited by Health Canada (1)
- Moskowitz RW. Role of collagen hydrolysate in bone and joint disease. Seminars in Arthritis and Rheumatism 2000;30(2):87-99. PubMed Randomised trial
- Trigonella foenum-graecum
Read the warning, when it applies and the studies cited
FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010; Mills et al. 2006; Hoffman 2003; Blumenthal et al. 2000).
Sources cited by Health Canada (4)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
- Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. An Evidence-Based Approach. New York (NY): Taylor and Francis; 2006.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Health Canada monograph dated 29 May 2026
FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Topical
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “EGT+Fisetin+Urolithin A”, https://compoatlas.com/en/supplements/canada/80147908-egt-fisetin-urolithin-a, updated 18 March 2026.